Prognostic factors for survival in esophageal squamous cell carcinoma (ESCC) patients with a complete regression of the primary tumor (ypTO) after neoadjuvant chemoradiotherapy (NCRT) followed by surgery

被引:7
|
作者
Kong, Min [1 ,2 ,3 ]
Shen, Jianfei [2 ]
Zhou, Chao [4 ]
Yang, Haihua [4 ]
Chen, Baofu [1 ,2 ,3 ]
Zhu, Chengchu [2 ]
Wang, Gongchao [1 ]
机构
[1] Shandong Univ, Shandong Prov Hosp, Dept Thorac Surg, Cheeloo Coll Med, 9677 Jingshi Rd, Jinan, Peoples R China
[2] Wenzhou Med Univ, Dept Cardiothorac Surg, Taizhou Hosp Zhejiang Prov, Taizhou, Peoples R China
[3] Taizhou Enze Med Ctr Grp, Enze Hosp, Dept Cardiothorac Surg, Taizhou, Peoples R China
[4] Wenzhou Med Univ, Dept Radiotherapy, Taizhou Hosp Zhejiang Prov, Taizhou, Peoples R China
关键词
Esophageal squamous cell carcinoma (ESCC); neoadjuvant chemoradiation; esophagectomy; prognostic factors; PREOPERATIVE CHEMORADIATION; COMPLETE RESPONSE; CANCER; EDITION;
D O I
10.21037/atm-20-4864
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: There are also differences in survival prognosis among esophageal squamous cell carcinoma (ESCC) patients with a complete regression of the primary tumor (ypT0) after Neoadjuvant chemoradiotherapy (NCRT) followed by surgery. And the purpose of this study was to investigate influencing factors from these different prognostic outcomes and their possible causes. Methods: The clinical data of 88 cases of ESCC patients with ypT0 after NCRT followed by surgery between 2011 and 2019 were retrospectively analyzed. The clinical and pathological prognostic factors that affect the survival were analyzed. Results: Sex, number of lymph nodes dissected, and pathologic positivity of lymph nodes may be significant in univariate analysis (P<0.1). Further multivariate analysis suggested that the pathologic positivity of the lymph nodes was an independent factor affecting prognosis (HR: 4.757, 95% CI: 2.195-10.313, P=0.000). Subsequently, the whole group was divided into a positive lymph node group (group LN+) and a negative lymph node group (group LN-) for comparison. The overall survival (OS) of group LN+ was significantly worse (HR: 0.211, 95% CI: 0.0336-0.239; P<0.0001), and recurrence-free survival (RFS) was significantly poorer in the LN+ group (HR: 0.0679, 95% CI: 0.0239-0.1923, P<0.0001). There were 14 cases of recurrence and metastasis in the LN+ group (14/21, 66.7%) and 10 cases in the group LN- (10/67, 14.9%). Among the sites of recurrence and metastasis, there were 10 (10/14, 71.4%) and 4 (4/14, 28.6%) cases of distant metastasis, respectively, and 4 (4/14, 28.6%) cases of local metastasis in the LN+ group; meanwhile, there were 8 (8/10, 80.0%) cases of distant metastasis and 2 (2/10, 20.0%) cases of local metastasis in the LN- group. Conclusions: The independent risk factor for survival prognosis in ESCC patients with ypT0 after NCRT followed by surgery was positive postoperative pathological lymph nodes. The reason for the shortened survival time associated with this group of patients was their susceptibility to recurrence and metastasis.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Change in Maximal Esophageal Wall Thickness Provides Prediction of Survival and Recurrence in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy and Surgery
    Wu, Yahua
    Li, Jiancheng
    [J]. CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 2433 - 2445
  • [42] A retrospective analysis of neoadjuvant chemotherapy followed by surgery or definitive chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma.
    Nakatsumi, Hiroshi
    Komatsu, Yoshito
    Nakano, Shintaro
    Sawada, Kentaro
    Muranaka, Tetsuhito
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Uchinami, Yusuke
    Taguchi, Hiroshi
    Shirato, Hiroki
    Ebihara, Yuma
    Shichinohe, Toshiaki
    Hirano, Satoshi
    Sakamoto, Naoya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [43] Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma Discussion
    Sugarbaker, David J.
    Molena, Daniela
    Swanson, Scott
    Decamp, Malcolm M.
    Weksler, Benny
    Lerut, Toni
    Chen, Ke-Neng
    Yang, Haoxian
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2018, 155 (06): : 2719 - +
  • [44] Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma
    Chao, Yin-Kai
    Chang, Hsien-Kun
    Tseng, Chen-Kan
    Liu, Yun-Hen
    Wen, Yu-Wen
    [J]. DISEASES OF THE ESOPHAGUS, 2017, 30 (02):
  • [45] A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis
    Deng, Wei
    Wang, Qifeng
    Xiao, Zefen
    Tan, Lijun
    Yang, Zhao
    Zhou, Zongmei
    Zhang, Hongxing
    Chen, Dongfu
    Feng, Qinfu
    Liang, Jun
    Li, Yexiong
    He, Jie
    Gao, Shugeng
    Sun, Kelin
    Cheng, Guiyu
    Liu, Xiangyang
    Fang, Dekang
    Xue, Qi
    Mao, Yousheng
    Wang, Dali
    Li, Jian
    [J]. ONCOTARGET, 2017, 8 (25) : 41102 - 41112
  • [46] Pretreatment Primary Tumor Stage is a Risk Factor for Recurrence in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response After Neoadjuvant Chemoradiotherapy
    La Mendola, Roberta
    Bencivenga, Maria
    Torroni, Lorena
    Alberti, Luca
    Sacco, Michele
    Casella, Francesco
    Ridolfi, Cecilia
    Simoni, Nicola
    Micera, Renato
    Pavarana, Michele
    Verlato, Giuseppe
    Giacopuzzi, Simone
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (06) : 3034 - 3043
  • [47] Pretreatment Primary Tumor Stage is a Risk Factor for Recurrence in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response After Neoadjuvant Chemoradiotherapy
    Roberta La Mendola
    Maria Bencivenga
    Lorena Torroni
    Luca Alberti
    Michele Sacco
    Francesco Casella
    Cecilia Ridolfi
    Nicola Simoni
    Renato Micera
    Michele Pavarana
    Giuseppe Verlato
    Simone Giacopuzzi
    [J]. Annals of Surgical Oncology, 2021, 28 : 3034 - 3043
  • [48] Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery
    Sugimura, Keijiro
    Miyata, Hiroshi
    Shinno, Naoki
    Ushigome, Hajime
    Asukai, Kei
    Yanagimoto, Yoshitomo
    Hasegawa, Shinnichiro
    Takahashi, Yusuke
    Yamada, Daisaku
    Yamamoto, Kazuyoshi
    Nishimura, Junichi
    Motoori, Masaaki
    Wada, Hiroshi
    Takahashi, Hidenori
    Yasui, Masayoshi
    Omori, Takeshi
    Ohue, Masayuki
    Yano, Masahiko
    [J]. ONCOLOGY, 2019, 97 (06) : 348 - 355
  • [49] Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma
    Liu, Guihong
    Chen, Tao
    Zhang, Xin
    Hu, Binbin
    Yu, Jiayun
    [J]. CANCER MEDICINE, 2024, 13 (05):
  • [50] Prognostic Significance of Lymphovascular Invasion in Patients with Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy
    Chen, Wei-Hsun
    Huang, Yen-Lin
    Chao, Yin-Kai
    Yeh, Chi-Ju
    Chang, Hsien-Kun
    Tseng, Chen-Kan
    Liu, Yun-Hen
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (01) : 338 - 343